The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional Study
The aim of this study was to assess the impact of low-volume metastasis (LVM) on disease-free survival (DFS) in women with apparent early-stage endometrial cancer (EC) who underwent sentinel lymph node (SLN) mapping. Patients with pre-operative early-stage EC were retrospectively collected from an i...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/7/2052 |
| _version_ | 1797608245820391424 |
|---|---|
| author | Alessandro Buda Cristiana Paniga Salih Taskin Michael Mueller Ignacio Zapardiel Francesco Fanfani Andrea Puppo Jvan Casarin Andrea Papadia Elena De Ponti Tommaso Grassi Jessica Mauro Hasan Turan Dogan Vatansever Mete Gungor Firat Ortag Sara Imboden Virginia Garcia-Pineda Stefan Mohr Franziska Siegenthaler Stefania Perotto Fabio Landoni Fabio Ghezzi Giovanni Scambia Cagatay Taskiran Robert Fruscio |
| author_facet | Alessandro Buda Cristiana Paniga Salih Taskin Michael Mueller Ignacio Zapardiel Francesco Fanfani Andrea Puppo Jvan Casarin Andrea Papadia Elena De Ponti Tommaso Grassi Jessica Mauro Hasan Turan Dogan Vatansever Mete Gungor Firat Ortag Sara Imboden Virginia Garcia-Pineda Stefan Mohr Franziska Siegenthaler Stefania Perotto Fabio Landoni Fabio Ghezzi Giovanni Scambia Cagatay Taskiran Robert Fruscio |
| author_sort | Alessandro Buda |
| collection | DOAJ |
| description | The aim of this study was to assess the impact of low-volume metastasis (LVM) on disease-free survival (DFS) in women with apparent early-stage endometrial cancer (EC) who underwent sentinel lymph node (SLN) mapping. Patients with pre-operative early-stage EC were retrospectively collected from an international collaboration including 13 referring institutions. A total of 1428 patients were included in this analysis. One hundred and eighty-six patients (13%) had lymph node involvement. Fifty-nine percent of positive SLN exhibited micrometastases, 26.9% micrometastases, and 14% isolated tumor cells. Seventeen patients with positive lymph nodes did not receive any adjuvant therapy. At a median follow-up of 33.3 months, the disease had recurred in 114 women (8%). Patients with micrometastases in the lymph nodes had a worse prognosis of disease-free survival compared to patients with negative nodes or LVM. The rate of recurrence was significantly higher for women with micrometastases than those with low-volume metastases (HR = 2.61; <i>p</i> = 0.01). The administration of adjuvant treatment in patients with LVM, without uterine risk factors, remains a matter of debate and requires further evaluation. |
| first_indexed | 2024-03-11T05:40:45Z |
| format | Article |
| id | doaj.art-64486975e54d4a4490946d99a7e1491c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T05:40:45Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-64486975e54d4a4490946d99a7e1491c2023-11-17T16:25:22ZengMDPI AGCancers2072-66942023-03-01157205210.3390/cancers15072052The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional StudyAlessandro Buda0Cristiana Paniga1Salih Taskin2Michael Mueller3Ignacio Zapardiel4Francesco Fanfani5Andrea Puppo6Jvan Casarin7Andrea Papadia8Elena De Ponti9Tommaso Grassi10Jessica Mauro11Hasan Turan12Dogan Vatansever13Mete Gungor14Firat Ortag15Sara Imboden16Virginia Garcia-Pineda17Stefan Mohr18Franziska Siegenthaler19Stefania Perotto20Fabio Landoni21Fabio Ghezzi22Giovanni Scambia23Cagatay Taskiran24Robert Fruscio25Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, ItalyDepartment of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, ItalyDepartment of Obstetrics and Gynecology, School of Medicine, Ankara University, 06620 Ankara, TurkeyInselspital, University Hospital of Bern, University of Bern, 3010 Bern, SwitzerlandGynecologic Oncology Unit, La Paz University Hospital, 28046 Madrid, SpainDepartment of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyDepartment of Obstetrics and Gynecology, Ospedale Santa Croce e Carle, 12100 Cuneo, ItalyDepartment of Obstetrics and Gynecology, ‘Filippo Del Ponte’ Hospital, University of Insubria, 21100 Varese, ItalyDepartment of Gynecology and Obstetrics, Ente Ospedaliero Cantonale, 6900 Lugano, SwitzerlandMedical Physics Department, Foundation IRCCS San Gerardo Hospital, 20900 Monza, ItalyDepartment of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, ItalyDivision of Gynecologic Oncology, Ospedale Michele e Pietro Ferrero, 12060 Verduno, ItalyDepartment of Obstetrics and Gynecology, İstanbul Training and Research Hospital, University of Health Sciences, 34766 İstanbul, TurkeyDepartment of Obstetrics and Gynecology, School of Medicine, Koc University, 34450 İstanbul, TurkeyDepartment of Obstetrics and Gynecology, School of Medicine, Acibadem University, 34750 İstanbul, TurkeyDepartment of Obstetrics and Gynecology, School of Medicine, Ankara University, 06620 Ankara, TurkeyInselspital, University Hospital of Bern, University of Bern, 3010 Bern, SwitzerlandGynecologic Oncology Unit, La Paz University Hospital, 28046 Madrid, SpainInselspital, University Hospital of Bern, University of Bern, 3010 Bern, SwitzerlandInselspital, University Hospital of Bern, University of Bern, 3010 Bern, SwitzerlandDivision of Gynecologic Oncology, Ospedale Michele e Pietro Ferrero, 12060 Verduno, ItalyDepartment of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, ItalyDepartment of Obstetrics and Gynecology, ‘Filippo Del Ponte’ Hospital, University of Insubria, 21100 Varese, ItalyDepartment of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyDepartment of Obstetrics and Gynecology, School of Medicine, Koc University, 34450 İstanbul, TurkeyDepartment of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, ItalyThe aim of this study was to assess the impact of low-volume metastasis (LVM) on disease-free survival (DFS) in women with apparent early-stage endometrial cancer (EC) who underwent sentinel lymph node (SLN) mapping. Patients with pre-operative early-stage EC were retrospectively collected from an international collaboration including 13 referring institutions. A total of 1428 patients were included in this analysis. One hundred and eighty-six patients (13%) had lymph node involvement. Fifty-nine percent of positive SLN exhibited micrometastases, 26.9% micrometastases, and 14% isolated tumor cells. Seventeen patients with positive lymph nodes did not receive any adjuvant therapy. At a median follow-up of 33.3 months, the disease had recurred in 114 women (8%). Patients with micrometastases in the lymph nodes had a worse prognosis of disease-free survival compared to patients with negative nodes or LVM. The rate of recurrence was significantly higher for women with micrometastases than those with low-volume metastases (HR = 2.61; <i>p</i> = 0.01). The administration of adjuvant treatment in patients with LVM, without uterine risk factors, remains a matter of debate and requires further evaluation.https://www.mdpi.com/2072-6694/15/7/2052endometrial cancerlow-volume metastasissentinel lymph node biopsyultrastagingrecurrence-free survival |
| spellingShingle | Alessandro Buda Cristiana Paniga Salih Taskin Michael Mueller Ignacio Zapardiel Francesco Fanfani Andrea Puppo Jvan Casarin Andrea Papadia Elena De Ponti Tommaso Grassi Jessica Mauro Hasan Turan Dogan Vatansever Mete Gungor Firat Ortag Sara Imboden Virginia Garcia-Pineda Stefan Mohr Franziska Siegenthaler Stefania Perotto Fabio Landoni Fabio Ghezzi Giovanni Scambia Cagatay Taskiran Robert Fruscio The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional Study Cancers endometrial cancer low-volume metastasis sentinel lymph node biopsy ultrastaging recurrence-free survival |
| title | The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional Study |
| title_full | The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional Study |
| title_fullStr | The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional Study |
| title_full_unstemmed | The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional Study |
| title_short | The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional Study |
| title_sort | risk of recurrence in endometrial cancer patients with low volume metastasis in the sentinel lymph nodes a retrospective multi institutional study |
| topic | endometrial cancer low-volume metastasis sentinel lymph node biopsy ultrastaging recurrence-free survival |
| url | https://www.mdpi.com/2072-6694/15/7/2052 |
| work_keys_str_mv | AT alessandrobuda theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT cristianapaniga theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT salihtaskin theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT michaelmueller theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT ignaciozapardiel theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT francescofanfani theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT andreapuppo theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT jvancasarin theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT andreapapadia theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT elenadeponti theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT tommasograssi theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT jessicamauro theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT hasanturan theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT doganvatansever theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT metegungor theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT firatortag theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT saraimboden theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT virginiagarciapineda theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT stefanmohr theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT franziskasiegenthaler theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT stefaniaperotto theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT fabiolandoni theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT fabioghezzi theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT giovanniscambia theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT cagataytaskiran theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT robertfruscio theriskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT alessandrobuda riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT cristianapaniga riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT salihtaskin riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT michaelmueller riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT ignaciozapardiel riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT francescofanfani riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT andreapuppo riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT jvancasarin riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT andreapapadia riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT elenadeponti riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT tommasograssi riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT jessicamauro riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT hasanturan riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT doganvatansever riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT metegungor riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT firatortag riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT saraimboden riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT virginiagarciapineda riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT stefanmohr riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT franziskasiegenthaler riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT stefaniaperotto riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT fabiolandoni riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT fabioghezzi riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT giovanniscambia riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT cagataytaskiran riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy AT robertfruscio riskofrecurrenceinendometrialcancerpatientswithlowvolumemetastasisinthesentinellymphnodesaretrospectivemultiinstitutionalstudy |